Put This Biotech at the Top of Your Must-Buy List on a Pullback

by Sam Collins | October 4, 2013 1:47 am

Celgene Corp. () — This company develops small molecule drugs for the treatment of blood-borne and solid-tumor cancers and inflammatory diseases. The stock has been on the Trade of the Day buy list[1] for over a year.

On Jan. 9[2], with CELG just above $ 91, I noted that S&P said it had “the brightest growth prospects among large-cap biotech companies.” And on March 18[3], at $111.25, I pointed out that it had broken from a cup-and-handle formation with a target of $125.

S&P has raised its target several times this year, and last month boosted it to $172 from $161. Consensus earnings estimates are for $5.96 per share this year and $7.22 in 2014.

Technically the stock is in a powerful bull channel with support roughly at its 50-day moving average. But CELG can be volatile, so even though my trading target is $180, I would prefer to buy it under $140. Long-term investors could take a partial position now and add to it in the event of a pullback.

Click to Enlarge

[4]

Source URL: https://investorplace.com/2013/10/trade-of-the-day-celgene-corp-celg/

---